6-溴-3,4-二氢-4,4-二甲基喹啉-2(1H)-酮 | 135631-90-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-溴-3,4-二氢-4,4-二甲基喹啉-2(1H)-酮
• 中文别名: 6-溴-3,4-二氢-4,4-二甲基喹-2(1H)-酮；6-溴-3,4-二氢-4,4-二甲基喹啉-2-(1H)-酮
• 英文名称: 6-bromo-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one
• 英文别名: 4,4-dimethyl-6-bromo-2-oxo-1,2,3,4-tetrahydroquinoline；6-Bromo-3,4-dihydro-4,4-dimethylquinolin-2(1H)-one；6-bromo-4,4-dimethyl-1,3-dihydroquinolin-2-one
• CAS: 135631-90-2
• 化学式: C₁₁H₁₂BrNO
• 分子量: 254.126
• InChiKey: FTRFIBKHXWYJAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-bromo-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-bromo-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one
CAS number: 135631-90-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H12BrNO
Molecular weight: 254.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-3,4-二氢-4,4-二甲基喹啉-2(1H)-酮 在 dimethyl sulfide borane 、 potassium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 57.0h， 生成 6-bromo-4,4-dimethyl-1-(propan-2-yl)-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  Practical synthetic strategies towards lipophilic 6-iodotetrahydroquinolines and -dihydroquinolines

  摘要：

  报道了使用三种实用、可扩展的合成方法合成新型四氢喹啉（THQ）和二氢喹啉（DHQ），以获得带有6-碘取代基的高脂溶性类似物。发现了一种多功能且稳定的喹啉-2-酮中间体，可以用硼烷试剂还原为相应的THQ，或者通过一种更有利于高温的新型消除反应用二异丁基铝氢化物还原为DHQ。将这些强电子给予的支架与电子受体基团偶联，导致所得结构表现出强荧光特性。

  DOI：

  10.3762/bjoc.12.174
• 作为产物：
  描述：

  3-甲基巴豆酰氯 在 吡啶 、 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 6.5h， 生成 6-溴-3,4-二氢-4,4-二甲基喹啉-2(1H)-酮
  参考文献：
  名称：

  髓样白血病中的新型抑制剂靶向信号转导子和转录5（STAT5）信号激活剂。

  摘要：

  信号转导子和转录激活因子5（STAT5s）是髓样白血病中酪氨酸激酶致癌基因的关键效应子。抑制STAT5将有助于降低白血病细胞的存活率，并且还可以增强其化学抗性。在第一个筛选实验中，我们确定命中13位能够抑制STAT5磷酸化和白血病细胞生长。的18个类似物的合成13使我们能够确定一种化合物，17F，作为具有最有效的抗白血病作用。17f抑制急慢性髓性白血病细胞的生长以及STAT5的磷酸化和转录活性。重要的是17楼对在造血细胞和白血病细胞的微环境中起重要作用的骨髓基质细胞的作用微乎其微。我们还证明了17f抑制STAT5，但不抑制STAT3，AKT或Erk1 / 2磷酸化。这些结果表明17f可能是针对髓样白血病中STAT5信号转导的新的先导分子。

  DOI：

  10.1021/acs.jmedchem.7b00369

文献信息

• HETEROCYCLICALLY SUBSTITUTED METHOXYPHENYL DERIVATIVES WITH AN OXO GROUP, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS
  申请人：KEIL Stefanie

  公开号：US20120004165A1

  公开（公告）日：2012-01-05

  Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments The invention relates to heterocyclically substituted methoxyphenyl derivatives with an oxo group, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R10, X, n, B 1 , B 2 , B 3 and B 4 are each defined as specified, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.

  含有氧代基的杂环取代甲氧基苯基衍生物，其制备方法及用途作为药物。该发明涉及含有氧代基的杂环取代甲氧基苯基衍生物，以及其生理兼容盐。该发明涉及以下式I的化合物 其中R1、R2、R3、R4、R10、X、n、B1、B2、B3和B4分别如规定所定义，以及其生理兼容盐。这些化合物适用于例如糖尿病的治疗。
• Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors
  申请人：Tsang Yin Kwok

  公开号：US20050148590A1

  公开（公告）日：2005-07-07

  Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR γ agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.

  式中变量的定义如规范中所述，对于预防或治疗哺乳动物的肺气肿和相关肺部疾病以及其他对RARγ激动剂类维生素A酸类药物敏感的疾病和病况是有用的，例如皮肤相关疾病，包括但不限于痤疮和牛皮癣。
• 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
  申请人：Sinha Santosh

  公开号：US20050004213A1

  公开（公告）日：2005-01-06

  Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.

  式中变量的含义如规范中定义的那样，这些化合物能够降低糖尿病哺乳动物的血清葡萄糖水平，而不会出现降低血清甲状腺素水平和短暂增加甘油三酯水平的不良副作用。
• Disubstituted acetylenes bearing heteroaromatic and heterobicyclic
  申请人：Allergan

  公开号：US05602130A1

  公开（公告）日：1997-02-11

  Retinoid-like activity is exhibited by compounds of the formula ##STR1## where X is S, O, or NR' where R' is hydrogen or lower alkyl; R is hydrogen or lower alkyl; A is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl or pyrazinyl; n is 0-4; and B is H, --COOH or a pharmaceutically acceptable salt, ester or amide thereof, --CH.sub.2 OH or an ether or ester derivative, or --CHO or an acetal derivative, or --COR.sub.1 or a ketal derivative where R.sub.1 is --(CH.sub.2).sub.m CH.sub.3 where m is 0-4, or a pharmaceutically acceptable salt thereof.

  化合物具有类似视黄醇的活性，其化学式为##STR1##其中X为S、O或NR'，R'为氢或较低的烷基；R为氢或较低的烷基；A为吡啶基、噻吩基、呋喃基、吡啶并嗪基、嘧啶基或吡嗪基；n为0-4；B为H、--COOH或其药学上可接受的盐、酯或酰胺，--CH.sub.2 OH或醚或酯衍生物，或--CHO或缩醛衍生物，或--COR.sub.1或缩酮衍生物，其中R.sub.1为--(CH.sub.2).sub.m CH.sub.3，m为0-4，或其药学上可接受的盐。
• [3-(C5-14ALKYL-2-OXO-1,2,3,4-TETRAHYDRO-QUINOLIN-6-YL)-3-OXO-PROPENYL]-PHENYL AND [3-(C5-14ALKYL-2-OXO-1,2,3,4- TETRAHYDRO-QUINOLIN-6-YL)-3-OXO-PROPENYL]-HETEROARYL DERIVATIVES HAVING ANTI-TUMOR ACTIVITY
  申请人：Allergan, Inc.

  公开号：US06683092B1

  公开（公告）日：2004-01-27

  Compounds of the formula where the variables have the meaning defined in the specification have anti-tumor activity.

  式中的化合物具有抗肿瘤活性。